Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Labile redox-active iron refers to a small, dynamic fraction of iron within cells or body fluids that is not tightly bound to proteins but is instead loosely associated with low-molecular-weight ligands. This pool of iron is characterized by its ability to readily participate in redox reactions and its amenability to exchange between different ligands. While essential for certain enzymatic functions, elevated levels can catalyze the formation of reactive oxygen species (ROS), leading to oxidative stress and tissue damage. It is a key component in iron overload diseases and plays a role in infection risk. Labile iron levels are influenced by dietary intake, iron storage, and chelation therapies.
Iron chelators bind to labile iron, preventing its participation in redox reactions and facilitating its removal from the body.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Labile Redox-active Iron (None).